SIAIS562055

SIAIS562055
Identifiers
  • 3-[4-[[12-[4-[[4-[[(1R)-1-[3-amino-5-(trifluoromethyl)phenyl]ethyl]amino]-7-methoxy-2-methyl-6-quinazolinyl]oxy]-1-piperidinyl]dodecyl]thio]-1,3-dihydro-1-oxo-2H-isoindol-2-yl]-2,6-piperidinedione
ChemSpider
Chemical and physical data
FormulaC49H62F3N7O5S
Molar mass918.13 g·mol−1
3D model (JSmol)
  • O=C1N(Cc2c(SCCCCCCCCCCCCN3CCC(Oc4cc5c(nc(C)nc5cc4OC)N[C@H](C)c4cc(N)cc(c4)C(F)(F)F)CC3)cccc12)C1CCC(=O)NC1=O

SIAIS562055 is an experimental anticancer drug which acts as a proteolysis targeting chimera (PROTAC) against the protein SOS1, acting by targeting this protein for destruction by cell maintenance enzymes. It was derived from the selective SOS1 inhibitor BI-3406. It is being researched for the treatment of some forms of leukemia as well as other cancers.[1]

See also

References

  1. ^ Luo Z, Lin C, Yu C, Yuan C, Wu W, Xu X, et al. (January 2025). "Targeted Degradation of SOS1 Exhibits Potent Anticancer Activity and Overcomes Resistance in KRAS-Mutant Tumors and BCR-ABL-Positive Leukemia". Cancer Research. 85 (1): 101–117. doi:10.1158/0008-5472.CAN-24-1093. PMC 11694061. PMID 39437162.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.